Skip to main content
Back to Investors

Eli Lilly Portfolio Companies

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

Last updated: June 2026

Eli Lilly Investment Overview

Portfolio Companies
110
Total Invested
$4.1B
Average Investment
$49.3M

Eli Lilly's Most Recent Investments (2020+)

Company NameFoundedFunding StageAmountCity
LTZ Therapeutics2026Venture - Series Unknown$40.0MSan Francisco
Cabaletta Bio2026Post-IPO EquityUndisclosedPhiladelphia
Remedium Bio2026Venture - Series UnknownUndisclosedNeedham
Incyclix Bio2026Series BUndisclosedDurham
Iterative Health2026Series CUndisclosedCambridge
Crossbow Therapeutics2026Series B$77.0MCambridge
Trogenix2025Series A$94.1MEdinburgh
Dualitas Therapeutics2025Series A$65.0MSan Francisco
Alchemab Therapeutics2025Series A$32.0MLondon
Syndeio Biosciences2025Venture - Series Unknown$90.0MIndianapolis

Complete List of Eli Lilly Portfolio Companies (110)

Export
#CompanyStageAmountLocation
1LTZ TherapeuticsVenture - Series Unknown$40.0MSan Francisco, United States
2Cabaletta BioPost-IPO EquityUndisclosedPhiladelphia, United States
3Remedium BioVenture - Series UnknownUndisclosedNeedham, United States
4Incyclix BioSeries BUndisclosedDurham, United States
5Iterative HealthSeries CUndisclosedCambridge, United States
6Crossbow TherapeuticsSeries B$77.0MCambridge, United States
7TrogenixSeries A$94.1MEdinburgh, United Kingdom
8Dualitas TherapeuticsSeries A$65.0MSan Francisco, United States
9Alchemab TherapeuticsSeries A$32.0MLondon, United Kingdom
10Syndeio BiosciencesVenture - Series Unknown$90.0MIndianapolis, United States
BiotechnologyHealth CareMedical

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

San Francisco, United States
May 2026
$40.0M
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareMedicalRoboticsTherapeutics

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Philadelphia, United States
May 2026
Post-IPO Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareTherapeutics

Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.

Needham, United States
May 2026
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CarePharmaceuticalTherapeutics

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

Durham, United States
April 2026
Series B

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)Clinical TrialsHealth CareHealth DiagnosticsMedical

Iterative Health develops technology that can benefit patients anywhere, regardless of socioeconomic or geographic barriers.

Cambridge, United States
April 2026
Series C

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceMedicalOncology

Crossbow Therapeutics is a biotech company that develops targeted therapies to address cancer antigens.

Cambridge, United States
March 2026
$77.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceMedicalTherapeutics

Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.

Edinburgh, United Kingdom
October 2025
$94.1M
Series A

Founder Contacts

19,000+ verified contacts

Biotechnology

Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders

San Francisco, United States
September 2025
$65.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalPharmaceutical

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

London, United Kingdom
September 2025
$32.0M
Series A

Founder Contacts

19,000+ verified contacts

Biotechnology

Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.

Indianapolis, United States
May 2025
$90.0M
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareMedicalTherapeutics

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

San Francisco, United States
May 2025
$39.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalTherapeutics

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

Boston, United States
April 2025
$41.0M
Series A

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyMachine Learning

Persist AI is a biotechnology company that builds long-acting microsphere formulations.

Woodland, United States
March 2025
$12.0M
Series A

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyMedicalTherapeutics

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

Boston, United States
March 2025
$65.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalTherapeutics

TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.

Cambridge, United States
March 2025
$31.0M
Seed

Founder Contacts

19,000+ verified contacts

Health CareMedicalPharmaceuticalTherapeutics

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Frederiksberg, Denmark
January 2025
$93.2M
Series A

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)MarketingPharmaceutical

Revisto is a pioneer AI-powered technology that simplifies the medical, legal, and regulatory review process for pharmaceutical marketing.

San Antonio, United States
November 2024
$4.0M
Seed

Founder Contacts

19,000+ verified contacts

BioinformaticsBiopharmaBiotechnology

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

South San Francisco, United States
November 2024
$84.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareMedical Device

Amprion is a biotech company that focuses on the diagnosis for brain diseases.

San Francisco, United States
September 2024
$6.0M
Series B

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)Health CareSoftware

Basys.ai automates the process of prior authorization and utilization management for health plans/payers using an AI-based platform.

Cambridge, United States
September 2024
$25K
Seed

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalTherapeutics

NanoSyrinx is a discovery stage biotechnology company based at the University of Warwick's Medical School.

Coventry, United Kingdom
September 2024
$13.1M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalPharmaceutical

Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.

Boston, United States
September 2024
$120.0M
Series A

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareMedicalTherapeutics

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

Palo Alto, United States
September 2024
$67.0M
Series B

Founder Contacts

19,000+ verified contacts

Health CareMedical Device

RetiSpec is a medical imaging startup developing an eye scanner for early detection of Alzheimer's Disease pathology.

Toronto, Canada
July 2024
$10.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

London, United Kingdom
July 2024
$115.3M
Series A

Founder Contacts

19,000+ verified contacts

Showing 1-25 of 110 portfolio companies

Frequently Asked Questions About Eli Lilly

How many companies has Eli Lilly invested in?

Eli Lilly has invested in 110 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Eli Lilly invest in?

Eli Lilly's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Pharmaceutical. The firm invests across 17 different industry categories.

What is Eli Lilly's largest investment?

Among tracked funding rounds, Superluminal Medicines received $120.0M in a Series A round. Eli Lilly's total known invested capital is $4.1B.

What is the average investment size for Eli Lilly?

Eli Lilly's average investment size is $49.3M across its portfolio of 110 companies.

What are Eli Lilly's most recent investments?

Recent Eli Lilly portfolio additions include LTZ Therapeutics, Cabaletta Bio, Remedium Bio, Incyclix Bio, Iterative Health. These companies were founded in 2020 or later.

Explore Other Top Investors

Discover portfolio companies of other leading venture capital firms and investors.

View All Investors